You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ICOS agonist monoclonal antibody

Showing 1 - 25 of 8,772
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cancer Trial in United States (JTX-2011, Nivolumab, Ipilimumab)

Completed
Has Results
  • Cancer
  • Palo Alto, California
  • +15 more
Sep 5, 2021

Cancer Trial in Canada, United States (Vopratelimab, Ipilimumab)

Active, not recruiting
  • Cancer
  • Beverly Hills, California
  • +20 more
Apr 4, 2022

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

Not yet recruiting
  • Primary Immune Thrombocytopenia (ITP)
  • TPO-RAs
  • TPO-RAs combining anti-CD 20 monoclonal antibody
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Feb 7, 2023

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in United

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
  • VLP-encapsulated TLR9 Agonist CMP-001
  • Scottsdale, Arizona
  • +3 more
Jun 1, 2022

Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • (no location specified)
Dec 15, 2022

Metastatic Triple Negative Breast Cancer Trial in Dallas (PLD Chemotherapy, CDX-1140, CDX-301)

Recruiting
  • Metastatic Triple Negative Breast Cancer
  • PLD Chemotherapy
  • +2 more
  • Dallas, Texas
    UT Southwestern Medical Center
Jun 23, 2022

NSCLC Trial in Worldwide (JTX-4014, Vopratelimab)

Active, not recruiting
  • NSCLC
  • Minsk, Belarus
  • +70 more
Jan 18, 2023

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 Trial in Los

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +5 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +3 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 31, 2023

Advanced Malignant Solid Tumor, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung Trial in Houston (drug,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +4 more
  • Anti-GITR Agonistic Monoclonal Antibody BMS-986156
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 30, 2021

Advanced Solid Tumor Trial in Australia, New Zealand, United States (BGB-A445, tislelizumab)

Recruiting
  • Phase 1a:Advanced Solid Tumors; Phase 1b: Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pittsburgh, Pennsylvania
  • +11 more
Aug 25, 2022

Cancer Trial in Saint Louis, Houston (Vopratelimab, Ipilimumab, Nivolumab)

Active, not recruiting
  • Cancer
  • Saint Louis, Missouri
  • +2 more
Sep 9, 2022

Recurrent Melanoma, Stage IV Melanoma Trial in Philadelphia (CD40 agonist mAb CP-870,893, tremelimumab, laboratory biomarker

Completed
  • Recurrent Melanoma
  • Stage IV Melanoma
  • CD40 agonist monoclonal antibody CP-870,893
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of The University of Pennsylvania
Apr 6, 2020

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Tumors Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a

Completed
  • Neoplasms
  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
  • MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
  • Scottsdale, Arizona
  • +26 more
Mar 31, 2022

Advanced/Metastatic Solid Tumors Trial in Kurralta Park, Clayton (ADG206)

Not yet recruiting
  • Advanced/Metastatic Solid Tumors
  • Kurralta Park, South Australia, Australia
  • +1 more
Nov 9, 2022

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Shanghai, China
    Zhongshan hospital, Fudan University
Aug 12, 2023

Metastatic Melanoma, Advanced Melanoma Trial in San Francisco (XmAb22841, XmAb23104)

Not yet recruiting
  • Metastatic Melanoma
  • Advanced Melanoma
  • San Francisco, California
    University of California, San Francisco
Jan 13, 2023

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Advanced Malignant Solid Tumor, Extracranial Solid Tumor, Metastatic Malignant Solid Tumor Trial in Palo Alto (Anti-OX40

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Anti-OX40 Antibody BMS 986178
  • TLR9 Agonist SD-101
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jun 13, 2022